Petvivo Holdings, INC 8-K filings

PetVivo Holdings, Inc. announced the resignation of its independent auditor, Stephano Slack LLC, effective July 2, 2026, and the engagement of GuzmanGray, A Professional Accountancy Corporation as its new auditor.

PetVivo Holdings has entered into a definitive merger agreement to acquire PiezoBioMembrane, Inc. to expand its functional biomaterials and regenerative medicine platform.

PetVivo Holdings has received the final $600,000 installment of a $1,000,000 private equity offering, with an option for further capital.

PetVivo Holdings, Inc. announced a private placement securing $1 million in equity financing with an option for an additional $1.5 million, aimed at funding commercialization and product development.

PetVivo Holdings, Inc. announced the resignation of Spencer Breithaupt from its Board of Directors, leading to a reduction in board size from seven to six members.

PetVivo Holdings, Inc. filed an 8-K to furnish an investor presentation for upcoming conferences and forums.

PetVivo Holdings, Inc. announced the resignation of Michael Eldred from its Board of Directors, leading to a reduction in board size from eight to seven members.

PetVivo Holdings, Inc. filed an 8-K to announce the availability of an investor presentation for upcoming conferences and forums.

PetVivo Holdings, Inc. has expanded its Board of Directors to eight members with the appointment of Josh Ruben, a seasoned expert in healthcare finance and capital markets.

PetVivo Holdings, Inc. converted $2.02 million in outstanding promissory notes held by four shareholders into 3.67 million shares of common stock.

PetVivo Holdings, Inc. announced the successful completion of its $5 million equity financing through the full exercise of a purchase option for Series B Convertible Preferred Stock.

PetVivo Holdings, Inc. announced the receipt of $3 million from a partial exercise of a purchase option, bringing the total equity financing received to date to $4 million out of a $5 million Series B Convertible Preferred Stock offering.

PetVivo Holdings, Inc. announced it has received $200,000 from a partial exercise of a purchase option, bringing the total raised in its $5 million Series B Convertible Preferred Stock offering to $1 million, with the remaining $4 million expected by June 26, 2025.

PetVivo Holdings, Inc. announced it has entered into a debt financing agreement with an existing shareholder for $160,000, convertible into common stock at $0.75 per share, and issued warrants for an additional 75,000 shares.

PetVivo Holdings, Inc. received $200,000 pursuant to a partial exercise of a Purchase Option and extended the option for an additional 30 days to allow an investor to invest the remaining $4.2 million of a $5 million Series B Convertible Preferred Stock Offering.

PetVivo Holdings, Inc. reports the resignation of Assurance Dimensions as their independent auditor due to the firm's exit from public company audits, and the engagement of Stephano Slack LLC as the new auditor, effective April 7, 2025.

PetVivo Holdings, Inc. announces a $5 million equity financing agreement through the issuance of Series B Convertible Preferred Stock, with an initial $600,000 received and an option for the investor to purchase the remaining $4.4 million within 60 days.

PetVivo Holdings, Inc. announces a $5 million equity financing agreement through the sale of Series B Convertible Preferred Stock, while still navigating the delisting process from Nasdaq.

PetVivo Holdings, Inc. has extended CEO John Lai's employment agreement to March 31, 2027, and amended his compensation, including a base salary of $150,000 per year.

PetVivo Holdings, Inc. entered into a promissory note agreement with a board member for $200,000, carrying a 12% interest rate and including a warrant for 100,000 shares.

PetVivo Holdings, Inc. announces that its wholly-owned subsidiary, PetVivo, Inc., will operate under the new name PetVivo Animal Health, Inc. effective March 1, 2025.

PetVivo Holdings has entered into promissory notes with two existing shareholders for a total of $500,000, which may be converted into common stock and include warrants for additional shares.

PetVivo Holdings secures an exclusive license and supply agreement with VetStem, Inc. to commercialize PrecisePRP canine and equine products, marking a significant step in veterinary regenerative medicine.

PetVivo Holdings, Inc. successfully completed a private placement, raising $617,500 through the sale of restricted common stock to accredited investors.

PetVivo Holdings, Inc. announces the elimination of the Chief Operating Officer position, effective January 31, 2025, as part of cost-cutting initiatives.

PetVivo Holdings, Inc. has released an investor presentation that will be used in investor conferences and other forums.

PetVivo Holdings, Inc. has released an investor presentation that will be used in various forums and on their website.

PetVivo Holdings has approved a new compensation policy for non-employee directors, including cash retainers, equity awards, and meeting fees.

PetVivo Holdings, Inc. reports the passing of its Chairman of the Board, James Martin, on September 28, 2024.

PetVivo Holdings has increased its board size and appointed Mike Eldred, former president of Dechra Pharmaceutical's North American operations, as a new independent director.